ARTICLE | Translation in Brief
Neoantigens in pediatric ALL could lead to cell-based therapies
Why a St. Jude's team thinks pediatric leukemia could be treated with neoantigen-targeted cell therapies
July 25, 2019 5:03 AM UTC
Despite low tumor mutation load, strong immune responses against predicted neoantigens suggest opportunities to develop immunotherapies for pediatric acute lymphoblastic leukemia.
The oncology field is increasingly turning to neoantigens -- non-self antigens arising from mutations in tumors -- as tumor-specific targets for personalized cell-based immunotherapies (see "Neo Wave")...
BCIQ Company Profiles